Tzvika Tzubery, Ph.D.

R&D Director

Dr. Tzubery is a seasoned academic and industrial researcher with over 10 years' experience in the diagnostics and medical device industries. Dr. Tzubery completed his doctoral, master's and undergraduate studies at the Hebrew University of Jerusalem, where he earned a Ph.D. in biochemistry, a M.Sc. in biotechnology and a B.S. in agricultural sciences. Before joining Neurogenic, Dr Tzubery was the R&D Project Manager at Novamed Ltd. and R&D Director at Syntezza Molecular Detection Ltd. He is currently leading the commercialization of the schizophrenia ELISA test.

Ms. Mila Shechtman, M.Sc.

Senior Scientist, Consultant

Ms. Schechtman is the former head of laboratory activities at Neurogenic and was one of the inventors of the schizophrenia immunoassay, along with Dr. Michael Deckmann, in the group of Prof. Meir Shinitzky. An organic chemist by training, Ms. Schechtman successfully completed the technology transfer process from the previous Neurogenic lab in the Weizmann Institute to the company's new facility in Weizmann Science Park, Ness Tziona, the cradle of Israeli biotech. After her recent retirement from the Weizmann Institute, she continues to be actively involved in the development of the assay in an advisory capacity.

Yossi Avnat


Yossi Avnat is the CEO of the Wolfson Clore Mayer group of companies for more than 20 years. He has B.A. and M.A. degrees in economics from the University of Tel Aviv and has more than 35 years of experience. He serves as a director in life science companies and as a director in Neurogenic since its inception.

Jonathan D. Leitersdorf

Investor representative

Jonathan Leitersdorf holds a Master of Architecture from the Architectural Association, School of Architecture, London and Masters of Science and Real Estate Development from Columbia University, New York City.
He is a member of the Board of Governors of Weizmann Institute of Science, Israel.
Mr. Leitersdorf resides in Verbier, Switzerland and his offices are located in Geneva, Tel-Aviv and New York. He is the representative of the family that is the principle shareholder of Neurogenic Ltd.

Oded Ben-Joseph, Ph.D. MBA

Advisory Board Member

Dr. Ben-Joseph is a Managing Director and Co-Lead of the Life Sciences Practice at Outcome Capital, a uniquely strategic investment banking firm located in Boston, MA, USA. He has over 20 years of experience in multiple aspects of the life sciences sector, bringing a combination of executive, entrepreneurial, scientific and transactional experience. Dr. Ben-Joseph was the CEO of several biotech and medtech companies and he also serves on several Boards. His academic appointments include Assistant Professor at the Departments of Radiology and Neuroscience at the University of Michigan, a Visiting Associate Professor at Tokushima University in Japan and a Visiting Scientist at Parke-Davis (Pfizer). Dr. Ben-Joseph has published numerous peer-review scientific papers as well as industry publications and has received several awards and scholarships.

Todd Wallach, MBA, MSE, MB

Advisory Board Member

Mr. Wallach is currently CEO and President of Evogen Inc., a commercial stage biothreat detection and diagnostics company. Mr. Wallach was formerly Chairman, CEO and a member of the founding management team of Molecular Detection Inc., a commercial stage molecular diagnostics company.  Previously, Mr. Wallach was CFO and a member of the founding management team of Aton Pharma, Inc. (Acquired by Valeant Pharmaceuticals), a specialty pharmaceutical company.  Prior to Aton Pharma, he was Vice President of Finance and Operations and a member of the founding management team of Acuity Pharmaceuticals (Now Opko, NASDAQ: OPK), a technology spin out from the University of Pennsylvania. He is serving in both diagnostic development and commercial advisory capacities.

Yechiel Goldman, Ph.D.

Scientific Writer, Consultant

For over 15 years, Dr. Goldman has been working as a regulatory affairs professional in the biotech/pharma sector in Israel. During this period, he has prepared a wide variety of regulatory, clinical and R&D documentation for submission to the FDA, EMA and Israeli MoH. He has extensive hands-on experience supporting US/EU/IL product development in oncology, neurology, cellular therapeutics and regenerative medicine.